Navigation Links
New Target for Muscular Dystrophy Drug Therapy Discovered

Researchers at the University of Pennsylvania School of Medicine have discovered a new target for the muscular dystrophy drug therapy .

The researchers have found how the gene for utrophin-which codes for a protein very similar to dystrophin, the defective protein in Duchenne muscular dystrophy (DMD)-puts the brakes on its own expression in muscle cells.

The production of utrophin slows in foetal muscles soon after birth, following which dystrophin takes over as the primary muscle-associated protein. How this normal utrophin silencing occurs has been a mystery for long, according to the background information in an article published online in Molecular Biology of the Cell.

Dr. Tejvir S. Khurana, Associate Professor of Physiology and Member of the Pennsylvania Muscle Institute, says the removal of silencing by drug intervention may help increase utrophin expression, which in turn may substitute for dystrophin as a possible therapy for DMD.

Experiments on mice have now shown that utrophin silencing is applied by a protein called Ets-2 repressor factor (ERF) sitting on a small piece of the utrophin gene called the N-box.

"We demonstrated that ERF significantly reduces or represses the activity of utrophin's N-box in muscle cells of mice," says Dr. Tejvir S. Khurana, 7senior author of the study.

During the study, the researchers noted that ERF did not have any effect on utrophin silencing when the N-box was deleted from the utrophin gene. They also observed that utophin mRNA production increased when ERF was repressed.

"This approach of 'repressing the repressor' is medically relevant to treating muscular dystrophy in that we hope to one day be able to upregulate utrophin production," explains Dr. Khurana.

Since the gene sequence of utrophin is over 80 per cent identical to that of dystrophin, it may substitute for dystrophin in muscle cells, says resea rchers.

Dr. Khurana, however, wants to ensure first whether repressing ERF reduces muscle deterioration in mice or not.

"We have worked on this problem for a number of years, and our current findings are a logical incremental step in understanding how utrophin could become an effective tool for treating DMD," states Dr. Khurana.


'"/>




Related medicine news :

1. Target for obesity treatment
2. Gel Offers A More Targeted Approach
3. In Search Of A New Drug To Target Cholesterol
4. In Search Of A New Drug To Target Cholesterol
5. Target of diabetes type 1 identified
6. Gene Target For Tuberculosis Identified
7. New Vaccine Targeted At Effective Treatment Against Tuberculosis
8. Novel Technique For Targeting Small-Cell Lung Cancer
9. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
10. Doctors, Pharma Companies Targeted By CBI Raids
11. Research Targets treatment for dementia and brain injuries
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... Phytomer USA ... As a Phytomer Account Manager, Smith’s role is to provide excellent customer ... that make up The Phytomer Group. Smith comes to Phytomer with a wealth of ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management ... officers for 2017-2018. The annual board election process has been in place since the ... , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology: